Does Metformin Reduce Cancer Risks? Methodologic Considerations (Q38687543)

5 September 2017

Does Metformin Reduce Cancer Risks? Methodologic Considerations (English)

1 reference

5 September 2017

1 reference

Asieh Golozar

1

1 reference

5 September 2017

Shuiqing Liu

2

1 reference

5 September 2017

Joeseph A Lin

3

1 reference

5 September 2017

Kimberly Peairs

4

1 reference

5 September 2017

Hsin-Chieh Yeh

5

1 reference

5 September 2017

1 January 2016

1 reference

5 September 2017

Current diabetes report

1 reference

5 September 2017

16

1 reference

5 September 2017

1

1 reference

5 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-015-0697-z

5 September 2017

0 references

cites work

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Diabetes, cancer, and metformin: connections of metabolism and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin and the risk of cancer: time-related biases in observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Time-window bias in case-control studies: statins and lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Increased cancer risk with drug use among patients with diabetes: Are the biased methods the culprit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

The effect of metformin and thiazolidinedione use on lung cancer in diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

The use of metformin and the incidence of lung cancer in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Diabetes and cancer: 5 years into the recent controversy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin and the risk of endometrial cancer: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Assessing the effect of treatment duration on the association between anti-diabetic medication and cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Case-control analysis on metformin and cancer of the esophagus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Association between metformin use and risk of prostate cancer and its grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin in cancer: translational challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Survival Bias Associated with Time-to-Treatment Initiation in Drug Effectiveness Evaluation: A Comparison of Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0697-Z

Metformin and the incidence of prostate cancer in patients with type 2 diabetes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26733059

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectives

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26733059

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26733059

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11892-015-0697-Z

1 reference

Dimensions Publication ID

5 September 2017

0 references

1 reference